Drug Profile
Research programme: hearing disorders - Decibel Therapeutics/Regeneron Pharmaceuticals
Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Decibel Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hearing loss; Tinnitus
Most Recent Events
- 25 Sep 2023 Decibel Therapeutics has been acquired by Regeneron Pharmaceuticals
- 28 Aug 2021 No recent reports of development identified for research development in Hearing loss in USA
- 28 Aug 2021 No recent reports of development identified for research development in Tinnitus in USA